Therapeutic signposts: Using biomarkers to guide better treatment of schizophrenia and other psychotic disorders

Medical Journal of Australia

Volumn 190, Issue 4 SUPPL., 2009, Pages

  Banati, Richard ^a,b   Hickie, Ian B ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b AUSTRALIAN NUCLEAR SCIENCE AND TECHNOLOGY ORGANISATION   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; BIOLOGICAL MARKER; BRAIN DERIVED NEUROTROPHIC FACTOR; N SEC BUTYL 1 (2 CHLOROPHENYL) N METHYL 3 ISOQUINOLINECARBOXAMIDE; NEUROLEPTIC AGENT;

ARTICLE; BIPOLAR DISORDER; BRAIN ATROPHY; COGNITIVE DEFECT; DEPRESSIVE PSYCHOSIS; DISEASE ACTIVITY; DISEASE SEVERITY; HEALTH STATUS; HUMAN; MICROGLIA; MISMATCH NEGATIVITY; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PSYCHOSIS; RISK ASSESSMENT; SCHIZOPHRENIA; SCORING SYSTEM; TREATMENT PLANNING;

EID: 61849179511     PISSN: 0025729X     EISSN: None     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2009.tb02371.x     Document Type: Article

References (52)

1. Waddington JL. Neuroimaging and other neurobiological indices in schizophrenia: relationship to measurement of functional outcome. Br J Psychiatry Suppl 2007; 50: s52-s57.
2. Potvin S, Stip E, Sepehry AA, et al. Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol Psychiatry 2008; 63: 801-808.
3. Muller N, Riedel M, Ackenheil M, Schwarz MJ. The role of immune function in schizophrenia: an overview. Eur Arch Psychiatry Clin Neurosci 1999; 249 Suppl 4: 62-68.
4. McGorry PD, Hickie IB, Yung AR, et al. Clinical staging of psychiatric disorders: a heuristic framework for choosing earlier, safer and more effective interventions. Aust N Z J Psychiatry 2006; 40: 616-622.
5. Bennett MR. Synapse formation and regression in the cortex during adolescence and in schizophrenia. Med J Aust 2009; 190 (4 Suppl): S14-S16.
6. Wood SJ, Pantelis C, Yung AR, et al. Brain changes during the onset of schizophrenia: implications for neurodevelopmental theories. Med J Aust 2009; 190 (4 Suppl): S10-S13.
7. Pantelis C, Velakoulis D, McGorry PD, et al. Neuroanatomical abnormalities before and after onset of psychosis: a cross-sectional and longitudinal MRI comparison. Lancet 2003; 361: 281-288.
8. Hickie I, Naismith S, Ward PB, et al. Reduced hippocampal volumes and memory loss in patients with early- and late-onset depression. Br J Psychiatry 2005; 186: 197-202.
9. Brewer WJ, Pantelis C, Anderson V, et al. Stability of olfactory identification deficits in neuroleptic-naive patients with first-episode psychosis. Am J Psychiatry 2001; 158: 107-115.
10. Banati RB. Visualising microglial activation in vivo. Glia 2002; 40: 206-217.
11. Duman RS, Monteggia LM. A neurotrophic model for stress-related mood disorders. Biol Psychiatry 2006; 59: 1116-1127.
12. Hickie I, Hickie C, Lloyd A, et al. Impaired in vivo immune responses in patients with melancholia. Br J Psychiatry 1993; 162: 651-657.
13. Hickie IB, Naismith SL, Ward PB, et al. Serotonin transporter gene status predicts cauclate nucleus but not amygdala or hippocampal volumes in older persons with major depression. J Affect Dis 2007; 98: 137-142.
14. McGrath J. Hypothesis: is low prenatal vitamin D a risk-modifying factor for schizophrenia? Schizophr Res 1999; 40: 173-177.
15. McGrath J, Eyles D, Mowry B, et al. Low maternal vitamin D as a risk factor for schizophrenia: a pilot study using banked sera. Schizophr Res 2003; 63: 73-78.
16. McGrath J, Saha S, Welham J, et al. A systematic review of the incidence of schizophrenia: the distribution of rates and the influence of sex, urbanicity, migrant status and methodology. BMC Med 2004; 2: 13.
17. Lakhan SE. Schizophrenia proteomics: biomarkers on the path to laboratory medicine? Diagn Pathol 2006; 1: 1.
18. Song JH, Kim H-J, Lee CH, et al. Identification of gene expression signatures for molecular classification in human leukemia cells. Int J Oncol 2006; 29: 57-64.
19. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005; 19 Suppl A: 5-36.
20. Craddock RM, Huang JT, Jackson E, et al. Increased alpha-defensins as a blood marker for schizophrenia susceptibility. Mol Cell Proteomics 2008; 7: 1204-1213.
21. Huang JTJ, Leweke FM, Oxley D, et al. Disease biomarkers in cerebrospinal fluid of patients with first-onset psychosis. PLoS Med 2006; 3: e428.
22. Gottesman II, Gould TD. The endophenotype concept in psychiatry: etymology and strategic intentions. Am J Psychiatry 2003; 160: 636-645.
23. Berrettini WH. Genetic bases for endophenotypes in psychiatric disorders. Dialogues Clin Neurosci 2005; 7: 95-101.
24. Bowden NA, Weidenhofer J, Scott RJ, et al. Preliminary investigation of gene expression profiles in peripheral blood lymphocytes in schizophrenia. Schizophr Res 2006; 82: 175-183.
25. Cardno AG, Rijsdijk FV, Sham PC, et al. A twin study of genetic relationships between psychotic symptoms. Am J Psychiatry 2002; 159: 539-545.
26. McDonald C, Bullmore ET, Sham PC, et al. Association of genetic risks for schizophrenia and bipolar disorder with specific and generic brain structural endophenotypes. Arch Gen Psychiatry 2004; 61: 974-984.
27. Craddock N, O'Donovan MC, Owen MJ. Genes for schizophrenia and bipolar disorder? Implications for psychiatric nosology. Schizophr Bull 2006; 32: 9-16.
28. Murray RM, Sham P, Van Os J, et al. A developmental model for similarities and dissimilarities between schizophrenia and bipolar disorder. Schizophr Res 2004; 71: 405-416.
29. Turkheimer FE, Aston JAD, Cunningham VJ. On the logic of hypothesis testing in functional imaging. Eur J Nucl Med Mol Imaging 2004; 31: 725-732.
30. Jernigan TL, Gamst AC, Fennema-Notestine C, Ostergaard AL. More μapping" in brain mapping: statistical comparison of effects. Hum Brain Mapp 2003; 19: 90-95.
31. Neumann J, Lohmann G, Derrfuss J, von Cramon DY. Meta-analysis of functional imaging data using replicator dynamics. Hum Brain Mapp 2005; 25: 165-173.
32. Uttal WR. The new phrenology: the limits of localizing cognitive processes in the brain. Cambridge, Mass: MIT Press, 2001.
33. Van Orden GC, Pennington BF, Stone GO. What do double dissociations prove? Cogn Sci 2001; 25: 111-172.
34. Donaldson DI. Parsing brain activity with fMRI and mixed designs: what kind of a state is neuroimaging in? Trends Neurosci 2004; 27: 442-444.
35. Bennett MR. Development of the concept of mind. Aust N ZJ Psychiatry 2007; 41: 943-956.
36. de Haas AH, Boddeke HW, Biber K. Region-specific expression of immunoregulatory proteins on microglia in the healthy CNS. Glia 2008; 56: 888-894.
37. Mittelbronn M, Dietz K, Schluesener HJ, Meyermann R. Local distribution of microglia in the normal adult human central nervous system differs by up to one order of magnitude. Acta Neuropathol 2001; 101: 249-255.
38. Ji KA, Eu MY, Kang SH, et al. Differential neutrophil infiltration contributes to regional differences in brain inflammation in the substantia nigra pars compacta and cortex. Glia 2008; 56:1039-1047.
39. Kanaan NM, Kordower JH, Collier TJ. Age and region-specific responses of microglia, but not astrocytes, suggest a role in selective vulnerability of dopamine neurons after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure in monkeys. Glia 2008; 56: 1199-1214.
40. Banati RB, Gehrmann J, Schubert R Kreutzberg GW. Cytotoxicity of microglia. Glia 1993; 7: 111-118.
41. Banati RB, Graeber MB. Surveillance, intervention and cytotoxicity: is there a protective role of microglia? Dev Neurosci 1994; 16: 114-127.
42. Raivich G, Banati R. Brain microglia and blood-derived macrophages: molecular profiles and functional roles in multiple sclerosis and animal models of autoimmune demyelinating disease. Brain Res Brain Res Rev 2004; 46: 261-281.
43. Jellinck PH, Kaufmann M, Gottfried-Blackmore A, et al. Selective conversion by microglia of dehydroepiandrosterone to 5-androstenediol-A steroid with inherent estrogenic properties. J Steroid Biochem Mol Biol 2007; 107: 156-162.
44. Nimmerjahn A, Kirchhoff F, Helmchen F. Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science 2005; 308: 1314-1318.
45. Sierra A, Gottfried-Blackmore A, Milner TA, et al. Steroid hormone receptor expression and function in microglia. Glia 2008; 56: 659-674.
46. Cagnin A, Brooks DJ, Kennedy AM, et al. In-vivo measurement of activated microglia in dementia. Lancet 2001; 358: 461-467. Erratum in: Lancet 2001; 358: 766.
47. Cagnin A, Myers R, Gunn RN, et al. In vivo visualization of activated glia by [11C] (R)-PK11195-PET following herpes encephalitis reveals projected neuronal damage beyond the primary focal lesion. Brain 2001; 124: 2014-2027.
48. Cagnin A, Rossor M, Sampson EL, et al. In vivo detection of microglial activation in frontotemporal dementia. Ann Neurol 2004; 56: 894-897.
49. Banati RB. Brain plasticity and microglia: is transsynaptic glial activation in the thalamus after limb denervation linked to cortical plasticity and central sensitisation? J Physiol Paris 2002; 96: 289-299.
50. Banati RB. Neuropathological imaging: in vivo detection of glial activation as a measure of disease and adaptive change in the brain. Br Med Bull 2003; 65: 121-131.
51. Hickie C, Hickie I, Silove D, et al. Delayed-type hypersensitivity skin testing: normal values in the Australian population. Int J Immunopharmacol 1995; 17: 629-634.
52. Bumke O. The dissolution of dementia praecox. Hist Psychiatry 1993; 4: 129-139. [Translation of: Die auflösung der dementia praecox. Klin Wochenschr 1932; 3: 437-440.]